Categories: Health

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

 | Source: BridgeBio Pharma, Inc.

PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on October 2, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 11 new employees in restricted stock units for an aggregate of 23,884 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio

GlobeNews Wire

Recent Posts

Andamanda Phuket Ranked in Trip Best 2025 Global Top 100 – A Must-Visit for Indian Families

Offering much more than just beaches, Andamanda Phuket — a Thai mythology-inspired water park — was recently…

29 minutes ago

From Grandstand to Every Person: Sting Makes F1 Dream a Reality for Fans

In a bold move that fuses cinema, culture, and adrenaline, Sting® Energy, PepsiCo India’s high-voltage…

29 minutes ago

Bybit Bridges the Future of Finance and Music at Tomorrowland Brasil 2025

Bybit Card brings real-world crypto utility to 45,000 festivalgoers at "Portal to the Future" stage…

30 minutes ago

Startek honored with the AAA DI-verse Certification for disability inclusion excellence

Recognition marks Startek's commitment to building an inclusive and accessible workplace for all MUMBAI, India, Oct.…

30 minutes ago

COTHM Pakistan and MindHYVE.ai Forge Strategic Partnership to Pioneer AI-Powered Hospitality Education

LAHORE, Pakistan, Oct. 24, 2025 /PRNewswire/ -- The College of Tourism & Hotel Management (COTHM…

31 minutes ago

MindHYVE.ai and Prime Institute of Health Sciences (PIHS) Launch Landmark AI Partnership to Transform Education and Healthcare in Pakistan

ISLAMABAD, Oct. 24, 2025 /PRNewswire/ -- MindHYVE.ai™, a global leader in agentic artificial intelligence and…

31 minutes ago